for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eli Lilly And Co

LLY.N

Latest Trade

154.17USD

Change

1.70(+1.11%)

Volume

7,875,456

Today's Range

152.04

 - 

154.50

52 Week Range

101.41

 - 

170.75

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
152.47
Open
152.04
Volume
7,875,456
3M AVG Volume
63.67
Today's High
154.50
Today's Low
152.04
52 Week High
170.75
52 Week Low
101.41
Shares Out (MIL)
956.47
Market Cap (MIL)
147,459.00
Forward P/E
21.39
Dividend (Yield %)
1.92

Next Event

Eli Lilly and Co to Discuss ESMO 2020 Presentations - Conference Call

Latest Developments

More

Lilly And Amgen Announce Manufacturing Collaboration For Covid-19 Antibody Therapies

U.S. FDA Grants Fast Track Designation To Jardiance To Improve Outcomes Following Heart Attack

Baricitinib In Combination With Remdesivir Reduces Time To Recovery In Hospitalized Patients With Covid-19 In NIAID-Sponsored ACTT-2 Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eli Lilly And Co

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry

Biotechnology & Drugs

Contact Info

Lilly Corporate Ctr

Drop Code 1094, Lilly Corporate Ctr

INDIANAPOLIS, IN

46285-0001

United States

+1.317.2762000

https://www.lilly.com/

Executive Leadership

David A. Ricks

Chairman of the Board, President, Chief Executive Officer

Joshua L. Smiley

Chief Financial Officer, Senior Vice President

Aarti Shah

Senior Vice President - Chief Information and Digital Officer

Daniel M. Skovronsky

Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories

Melissa Stapleton Barnes

Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer

Key Stats

2.29 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.9K

2018

24.6K

2019

22.3K

2020(E)

23.9K
EPS (USD)

2017

4.280

2018

5.550

2019

6.040

2020(E)

7.269
Price To Earnings (TTM)
25.08
Price To Sales (TTM)
6.43
Price To Book (MRQ)
36.03
Price To Cash Flow (TTM)
21.54
Total Debt To Equity (MRQ)
398.94
LT Debt To Equity (MRQ)
368.06
Return on Investment (TTM)
19.88
Return on Equity (TTM)
13.93

Latest News

Latest News

Eli Lilly's drug cuts COVID-19 recovery time in remdesivir-combo study

Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc's remdesivir.

Eli Lilly's rheumatoid arthritis drug helps recovery in COVID-19 patients

Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from COVID-19 in hospitalized patients in a clinical trial.

BRIEF-Fauci Expects Results From ACTIV-2 Study On Lilly's Antibody Drug By Oct. Or Nov.

* NIH'S FAUCI SAYS EXPECTS RESULTS ON EFFECTIVENESS OF ELI LILLY'S ANITBODY TREATMENT IN MILD TO MODERATE COVID-19 FROM ACTIV-2 TRIAL BY OCT. OR EARLY NOV. Further company coverage:

BRIEF-Eli Lilly And Co Announced Full Results From EMPERIAL Exercise Ability Trials Presented

* ELI LILLY AND CO - FULL RESULTS FROM EMPERIAL EXERCISE ABILITY TRIALS PRESENTED

BRIEF-Eli Lilly's Emgality Showed Reduction In Frequency, Duration And Migraine Pain Severity

* EMGALITY® DEMONSTRATES REDUCTION IN FREQUENCY, DURATION, AND PAIN SEVERITY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE

Lilly's breast cancer drug succeeds in study, shares rise 11%

Eli Lilly and Co said on Tuesday its treatment, Verzenio, met the trial goal of reducing the risk of early-stage breast cancer returning, sending the company's shares up 11%.

SCOTUS won't hear appeal of Eli Lilly patent win in blockbuster cancer drug case

The U.S. Supreme Court on Monday declined to hear an appeal by two generic drug companies of a patent law decision that preserved Eli Lilly & Co's monopoly on the chemotherapy drug Alimta until 2022.

BRIEF-Eli Lilly Says Verzenio With Standard Adjuvant Endocrine Therapy Met Primary Endpoint Of Invasive Disease-Free Survival

* VERZENIO® (ABEMACICLIB) SIGNIFICANTLY REDUCED THE RISK OF CANCER RETURNING IN PEOPLE WITH HIGH RISK HR+, HER2- EARLY BREAST CANCER

Eli Lilly starts trial of rheumatoid arthritis drug in COVID-19 patients

Eli Lilly and Co on Monday said it was launching a study of its rheumatoid arthritis drug baricitinib in patients hospitalized for COVID-19.

Eli Lilly starts late-stage study of arthritis drug in COVID-19 patients

U.S. drugmaker Eli Lilly and Co said on Monday it has started a late-stage trial testing its rheumatoid arthritis drug Olumiant in patients hospitalized with COVID-19.

Eli Lilly starts late-stage study of arthritis drug in COVID-19 patients

U.S. drugmaker Eli Lilly and Co said on Monday it has started a late-stage trial testing its rheumatoid arthritis drug Olumiant in patients hospitalized with COVID-19.

BRIEF-Lilly Announces Start Of Phase 1 Study For Second Potential COVID-19 Antibody Treatment

* LILLY ANNOUNCES START OF A PHASE 1 STUDY FOR ITS SECOND POTENTIAL COVID-19 ANTIBODY TREATMENT

BRIEF-Eli Lilly - Taltz Shows Consistent Efficacy & Long-Term Potential To Help Patients With Psoriatic Arthritis In New Data

* ELI LILLY - TALTZ SHOWED CONSISTENT EFFICACY & LONG-TERM POTENTIAL TO HELP PATIENTS WITH PSORIATIC ARTHRITIS IN NEW DATA TO BE PRESENTED AT EULAR 2020

Eli Lilly starts human study of potential COVID-19 antibody treatment

Eli Lilly and Co said on Monday it had started an early-stage trial to test its potential treatment for COVID-19, in the world's first study of an antibody treatment against the disease.

Eli Lilly starts human study of potential COVID-19 treatment

Eli Lilly and Co said on Monday patients have been dosed to test its potential antibody treatment designed to fight COVID-19, caused by the new coronavirus.

BRIEF-Lilly Receives FDA Approval Of Tauvid For Patients Being Evaluated For Alzheimer's Disease

* LILLY RECEIVES U.S. FDA APPROVAL OF TAUVID™ (FLORTAUCIPIR F 18 INJECTION) FOR USE IN PATIENTS BEING EVALUATED FOR ALZHEIMER'S DISEASE

Lilly, Junshi Biosciences plan to start human trials of COVID-19 antibody in second quarter

Shanghai Junshi Biosciences Co Ltd said on Tuesday it plans to start clinical studies to test its experimental antibody against COVID-19 in the United States and China in the second quarter of the year, with partner Eli Lilly and Co.

Lilly, Junshi Biosciences to start human trials of COVID-19 antibodies

Shanghai Junshi Biosciences Co Ltd said on Tuesday it planned to start clinical studies to test its experimental COVID-19 antibodies, developed with partner Eli Lilly and Co, by the second quarter of the year in the United States and China.

BRIEF-Emgality Shows Improvement In Work Productivity And Health And Well-Being Between Attacks In Patients With Migraine And A History Of Preventive Treatment Failure

* EMGALITY® SHOWS IMPROVEMENT IN WORK PRODUCTIVITY AND HEALTH AND WELL-BEING BETWEEN ATTACKS IN PATIENTS WITH MIGRAINE AND A HISTORY OF PREVENTIVE TREATMENT FAILURE

BRIEF-Eli Lilly - Study Results Demonstrate Societal Cost Burden During Early Stages Of Alzheimer's Disease

* RESULTS OF GERAS-US STUDY DEMONSTRATE SOCIETAL COST BURDEN FOR PATIENTS AND CAREGIVERS DURING EARLY STAGES OF ALZHEIMER'S DISEASE Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up